Shattuck Labs Inc (NAS:STTK)
$ 7.915 0.075 (0.96%) Market Cap: 376.37 Mil Enterprise Value: 265.75 Mil PE Ratio: 0 PB Ratio: 2.92 GF Score: 62/100

Shattuck Labs Inc at Citi BioPharma Conference Transcript

Sep 08, 2022 / 06:40PM GMT
Release Date Price: $3.51 (+5.09%)
Yigal Nochomovitz
Citigroup Inc. - Director

Great. So I mean, (inaudible) someone [at] the biotech analysts here at Citi. So this is the targeted oncology panel, always going to be a very exciting topic. So we have three excellent CEOs here from different companies around the country, from Shattuck Labs, Taylor Schreiber, CEO. Welcome Avanish Vellanki, Rain Therapeutics CEO. Welcome; and Bill Lundberg, CEO of Merus. Welcome to all of you. There is a fourth person, Jacob Chacko. Hopefully, he will show up soon from ORIC.

So maybe we'll just -- not everybody is super familiar with what you're doing. So let's not go in for a long discussion but just maybe a two- to three-minute quick overview of your pipeline. What are your key assets? What are the key data points that we should be looking forward to in the next year or so?

Taylor Schreiber
Shattuck Labs, Inc. - Co-Founder, Director, CEO

(multiple speakers) All right so I'll go first. So I'm Taylor Schreiber, CEO of Shattuck Labs. What Shattuck is developing is a series of dual sided Fc fusion proteins

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot